NEW YORK – Healthcare technology company Velsera said Tuesday that it has inked a partnership with molecular diagnostics firm Diagnóstica Longwood to accelerate the adoption of sequencing-based precision medicine in Spain and Portugal.
Financial terms of the deal were not disclosed.
As part of the agreement, the companies will leverage Boston-based Velsera's Clinical Genomics Workspace (CGW) platform, a genetic data analysis platform for oncology and inherited diseases, with Zaragoza, Spain-based Diagnóstica Longwood's distribution network and regional knowledge. The partnership aims to boost access to next-generation sequencing-based diagnostic solutions for healthcare providers in Spain and Portugal, according to the companies.
"We are excited to partner with Velsera to bring advanced genomics solutions to the Iberian market," Diagnóstica Longwood CSO Rosario Sanches said in a statement. "Our shared vision for empowering healthcare providers with advanced NGS technology will drive precision medicine and enhance patient care across Spain and Portugal."